Loading…
In the context of Fecal Microbiota Transplantation (FMT) & Metabolic Syndrome (MetS), experimental data suggest treating obesity and other disorders associated with metabolic syndrome with Fecal Microbiota Transplantation (FMT) (1)
A meta-analysis including nine studies, comprising 303 participants revealed that Fecal Microbiota Transplantation (FMT) does not produce any serious adverse effects and may be beneficial as an adjunctive therapy in the treatment of metabolic syndrome, especially in improving blood glucose, increasing insulin sensitivity, and HDL cholesterol. However, due to the small number of relevant studies and the low quality of evidence, we need more high-quality studies on the role of FMT in the metabolic processes of glucose and lipids. Moreover, the fact that the FMT application is associated with changes in obesity-related parameters needs further confirmation when we include diet and lifestyle changes in the design (5).
NCT02050607
Results are not uniquely traceable in the published record as of January 2026
NCT02496390
demonstrated that FMT did not improve insulin resistance, as measured by HOMA-IR or hepatic PDFF. Nonetheless, it indicated a potential to reduce small intestinal permeability in patients with NAFLD (4)
NCT03020186
revealed that first improve the microbiome with a green, plant-rich, polyphenol-rich diet, then autologous FMT may help maintain some of that benefit during the regain phase (8)
NTR 4338
revealed that in patients with metabolic syndrome, a single fecal microbiota transplantation from a lean vegan donor led to noticeable alterations in the composition of their gut microbiota. However, this intervention did not succeed in bringing about changes in the production capacity of TMAO or in parameters associated with vascular inflammation (6).
The clinical trial NTR1776 - Fecal Microbiota Transplantation (FMT) allogenic vs Fecal Microbiota Transplantation (FMT) autologous & Metabolic syndrome (MeS) demonstrated significant findings. Six weeks following the infusion of microbiota from lean donors, there was an increase in the insulin sensitivity of the recipients. Specifically, the median rate of glucose disappearance improved from 26.2 to 45.3 µmol/kg/min, with a statistical significance of P < .05. Additionally, there was an increase in the levels of butyrate-producing intestinal microbiota. These results suggest that intestinal microbiota could potentially be developed as therapeutic agents to enhance insulin sensitivity in humans (3)
The randomized clinical trial NTR4327 - Fecal Microbiota Transplantation (FMT) after bariatric surgery vs Fecal Microbiota Transplantation (FMT) before bariatric surgery & Metabolic syndrome (MetS) demonstrated that allogenic Fecal Microbiota Transplantation (FMT) using metabolic syndrome donors (MeTs-D) reduces insulin sensitivity in recipients with metabolic syndrome when compared to using post-roux-en-Y gastric bypass donors (rYgB-D). Additional research is necessary to clarify the impact of donor characteristics on the effectiveness of FMT in individuals with insulin resistance (2)
In the randomized clinical trial XXX - Fecal Microbiota Transplantation (FMT) (allogenic from lean donors) vs Fecal Microbiota Transplantation (FMT) (autologous) & Metabolic syndrome (MetS), it was discovered that the positive impact of lean donor fecal microbiota transplantation (FMT) on glucose metabolism is associated with alterations in gut microbiota and plasma metabolites. Furthermore, these effects can be anticipated by examining the initial composition of the fecal microbiota (7).
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
see also:
Dysbiosis & Metabolic Syndrome (MetS)
Fecal Microbiota Transplantation (FMT) & Adiposity / Obesity
Fecal Microbiota Transplantation (FMT) + Low-fermentable (LF) fibers & Metabolic syndrome (MetS)
Metabolic Syndrome (MetS) & Drugs/Treatments